Ascendiant raised the firm’s price target on 60 Degrees Pharmaceuticals to $1.30 from $1.20 and keeps a Buy rating on the shares. The company reported in-line Q4 results while Q4 babesiosis trials and malaria marketing initiatives are underway, the analyst tells investors in a research note. The firm cites incremental business progress for the target bump.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharmaceuticals to sponsor pilot study of tafenoquine
- 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
- 60 Degrees announces FDA communication on trial protocol submission
- 60 Degrees Pharmaceuticals Embarks on Tafenoquine Research Partnership
- 60 Degrees Pharmaceuticals to sponsor pre-clinical studies of Tafenoquine use
